BioXcel Therapeutics, Inc. (BTAI)
0.0739
-0.04
(-37.11%)
USD |
NASDAQ |
Sep 04, 16:00
0.0434
-0.03
(-41.27%)
After-Hours: 20:00
BioXcel Therapeutics Total Liabilities (Quarterly) : 144.26M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 144.26M |
| March 31, 2026 | 139.57M |
| December 31, 2025 | 142.98M |
| September 30, 2025 | 133.71M |
| June 30, 2025 | 133.46M |
| March 31, 2025 | 128.74M |
| December 31, 2024 | 131.44M |
| September 30, 2024 | 134.52M |
| June 30, 2024 | 139.74M |
| March 31, 2024 | 154.69M |
| December 31, 2023 | 130.21M |
| September 30, 2023 | 141.06M |
| June 30, 2023 | 134.23M |
| March 31, 2023 | 127.10M |
| December 31, 2022 | 129.08M |
| September 30, 2022 | 117.83M |
| June 30, 2022 | 83.97M |
| March 31, 2022 | 17.02M |
| December 31, 2021 | 17.77M |
| September 30, 2021 | 15.78M |
| Date | Value |
|---|---|
| June 30, 2021 | 13.70M |
| March 31, 2021 | 13.65M |
| December 31, 2020 | 13.24M |
| September 30, 2020 | 17.81M |
| June 30, 2020 | 17.07M |
| March 31, 2020 | 13.23M |
| December 31, 2019 | 9.497M |
| September 30, 2019 | 9.277M |
| June 30, 2019 | 9.121M |
| March 31, 2019 | 7.96M |
| December 31, 2018 | 4.66M |
| September 30, 2018 | 2.043M |
| June 30, 2018 | 1.389M |
| March 31, 2018 | 4.215M |
| December 31, 2017 | 2.337M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.331M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 46.19M |
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
| Imunon, Inc. | 10.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 28.80M |
| Shareholders Equity (Quarterly) | -115.46M |
| Debt to Equity Ratio | -0.9047 |
| Current Ratio | 0.2093 |
| Net Debt Paydown Yield | 0.66% |